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Abstract 
Introduction: Hypogonadism is estimated to 
affect between 2.1 and 12.8% of the adult male 
population.  
Aim:  The aim of this audit is to look at current 
practice and compare them with established 
guideline so as to identify areas which need 
improvement.  
Method:  A review of 235 patients suffering 
from hypogonadism was undertaken.  Local 
standards of care were compare to the Endocrine 
Society Clinical Practice Guideline of 2010 
(ESCG). 
Results:  Patients complained of 0, 1-4, 5-8 
symptoms suggestive of hypogonadism in 17%, 
67% and 16% respectively.  76.5% of the patients 
had repeatedly low testosterone.  20% suffered from 
primary hypogonadism.  77% suffered from 
secondary hypogonadism secondary.   Karyotype 
was obtained in 35% and 5% of the patients 
suffering from primary and secondary 
hypogonadism respectively.  Patients suffering from 
secondary hypogonadism had serum TSH (94%), 
prolactin (92%), cortisol (91%), GH levels (89%) 
and iron studies (43%) analysed.  77% of patients 
suffering from secondary hypogonadism had an 
MRI of the pituitary, with an abnormality reported 
in 53% of the patients.  Prior to starting treatment 
7% of the patients were assessed for prostate 
nodules and PSA was taken in 39% of the patients. 
Only 33% of the patients had bone mineral density 
(BMD) taken prior to starting testosterone 
treatment.   Patients were reviewed 3-6 months 
(35%) and then annually (88%) after treatment was 
initiated.   
Conclusion: This audit identifies the need for 
documentation of signs and symptoms.  
Testosterone levels should be repeated prior to 
starting treatment.  It also highlights the need for 
karyotyping in patients with primary hypogonadism 
as well as the need to measure BMD and PSA 
before and after prescribing testosterone.  Patients 
need review at 3-6months after initiation of 
testosterone supplementations.  
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Introduction 
Testosterone deficiency  is defined as sub-
optimal serum testosterone levels with or without 
modified receptor sensitivity to androgens.1  It may 
be further described as clinical hypogonadism 
(presence of signs and symptoms), or as subclinical 
hypogonadism (a biochemical deficiency with 
absence of symptom) and is estimated to affect 
between 2.1% and 12.8% of adult males.2-3 
Testosterone deficiency can result from defects 
at different levels of the hypothalamus-pituitary-
testes axis, ranging from abnormalities in the testes 
(primary hypogonadism), to pituitary or 
hypothalamic dysfunction (secondary 
hypogonadism).4  Testosterone deficiency may also 
occur due to decreased bioavailability of the 
hormone (due to sex hormone binding variations) or 
androgen receptor alterations.4 
Presentations includes sexual dysfunction, 
fatigue, mood disturbances, decline in bone mineral 
density (BMD) and change in body composition, 
erectile dysfunction, decrease morning erections 
and low libido being of greatest significance.2,4-5  
Due to its numerous influences on the endocrine 
and nervous system, testosterone deficiency is 
associated with a variety of co-morbidities 
including obesity, type 2 diabetes, hypertension, 
osteoporosis and cardiovascular disease. 1-2 
A definite diagnosis can be established after 
two morning total serum testosterone levels, with 
cut-off values depending on different methodology 
used.2, 5-7 Treatment options for hypogonadism 
revolve around testosterone replacement therapy. 1-2, 
6-7 
An audit was carried out with the aim of 
investigating patient demographists, clinical 
investigation, treatment and follow up of 
hypogonadal patients at Mater Dei Hospital.  These 
findings were compared to the Endocrine Society 
Clinical Practice Guideline of 2010 (ESCG) 
regarding identification, diagnosis, investigations 
and managing patients with androgen deficiency 
syndromes.7  
 
Aim 
The aim of this audit was to review current 
practices in Mater Dei Hospital and compare them 
with established guidelines so as to identify areas 
which need improvement.  
 
Patients and Methods 
Sample  
235 patients prescribed testosterone esters and listed 
on the Medical Approval Section covering 
entitlement for free medication from 2006 until 
February 2014 were included.  Data analysis was 
carried out on 153 i.e. 65% of the cohort.  In 29% of 
the cohort no data was available in their file while 
in 6% of the cohort the file could not be accessed. 
Case notes of adult males seen at Mater Dei 
Hospital who were on testosterone treatment were 
reviewed.   
 
Methodology  
This was an audit were medical notes and 
online documentation systems (Isoft® and PACS®) 
were used to collect data on the patients’ diagnosis 
and management.  The data collection form used 
was based on the ESCG.7  Data collection was done 
using Microsoft Access® and then data analysis was 
carried out by using Microsoft Excel® using simple 
descriptive statistics.   Analysis for concordance 
with ESCG recommendations was subsequently 
carried out. 
 
Results 
Patient demographic and symptomatology  
Data analysis was carried out on 153 patients 
(n).  30% (n=46) of the patients were below 29 
years of age, 57% (n=87) were between 30 and 59 
years of age and 13% (n=20) were above 60 years 
of age (Figure 1).  ).  2 patients who suffered from 
hypogonadism secondary to multiple system 
atrophy and pituitary adenoma were over 70 years 
of age.  The most common symptoms that the 
patients complained of were a decrease in 
spontaneous erections, reduced libido, small testes 
and reduced body hair (Figure 2).  Patients 
complained of 0, 1-4, 5-8 symptoms suggestive of 
hypogonadism in 17% (n=26), 67% (n=102) and 
16% (n=25) respectively (Figure 3). 
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Figure 1: Age when testosterone treatment was started. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Symptoms and signs at presentation. 
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Figure 3: Percentage number of patients with 0 to 8 symptoms at presentation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Investigation 
During data collection, testosterone levels were 
found to be below the lower limit of normal for the 
particular assay used.  Different assays which were 
used over the years include enzyme–linked 
immunosorbent assay and chemiluminescent 
immunoassay.    Due to the utilisation of different 
assays for total and/or free testosterone, different 
normative ranges were present over different time 
periods, hence graphical representations of these 
levels was not possible.  However, 76.5% (n=117) 
of the patients had confirmation of low testosterone 
by repeat analysis prior to starting treatment.  Sex 
hormone binding globulin (SHBG) was measured in 
2 patients.   However a number of patients (n=90) 
had conditions which could potentially affect 
SHBG concentration.   
Karyotype was obtained in 35% (n=11) and 5% 
(n=6) of the patients suffering from primary and 
secondary hypogonadism respectively.  Patients 
suffering from secondary hypogonadism had serum 
TSH (94%; n=110), prolactin (92%; n=108), 
cortisol (91%; n=107), GH (89%; n=104) and iron 
studies (43%; n=50) taken (Figure 4, 5). Of the 117 
patients who suffered from secondary 
hypogonadism, 90 patients had an MRI of the 
pituitary, with an abnormality reported in 62 of the 
patients.   
 
Diagnosis 
20% (n=31) suffered from primary 
hypogonadism with Klinefelter's syndrome (5%; 
n=7) and orchidectomy (4%; n=6) being the most 
common causes (Figure 6).  In 7 patients the cause 
was not found.  77% (n=117) suffered from 
secondary hypogonadism with pituitary adenoma 
(31%; n=47) and idiopathic hypogonadotrophic 
hypogonadism (14%; n=21) being the most 
common causes (Figure 7).  16 patients had no MRI 
done.  3% (n=5) of the patients could not be 
classified as suffering from primary or secondary 
hypogonadism since LH and FSH levels were not 
available.   
 
Treatment and follow up 
No patient had a past history of breast or 
prostate cancer. 78 of the patients were over 40 
years old when testosterone treatment was started.  
PSA was tested in 42 (54%) of these patients.  23 of 
these patients had a PSA less than 0.6ng/ml.  On the 
other hand, 19 of these patients had a PSA more 
than 0.6ng/ml with only half of these having a 
digital rectal examination performed.   
Testosterone undecanoate and testosterone 
enanthate were the most commonly used 
testosterone esters. (Table 1)  
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Figure 4: Percentage of patients with hypergonadotrophic hypogonadism with karyotyping and hormone 
profiles 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Percentage of patients with hypogonadotrophic hypogonadism with karyotyping and hormone 
profiles 
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Figure 6: Causes of primary hypogonadism (Hypergonadotrophic hypogonadism) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Causes of secondary hypogonadism (hypogonadotropic hypogonadism) 
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Table 1: Type of testosterone esters used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Bone mineral density results. 
 
BMD at 
diagnosis 
Mean T score 
of the spine  at 
diagnosis        
(+/- SD) 
Mean T score 
of the spine  
after starting 
treatment       
(+/- SD) 
Mean T score 
of the hip  at 
diagnosis        
(+/- SD) 
Mean T score 
of the  hip  
after starting 
treatment 
(+/- SD) 
Normal (3pts) -0.14 (+/- 0.61) 0.15 (+/- 0.23) 0.02 (+/-0.70) -0.25 (+/- 1.36) 
Osteopenia 
(9pts) 
-1.59 (+/- 0.51) -1.41 (+/- 1.18) -1.15 (+/- 0.96) -1.40 (+/- 0.41) 
Osteoporosis 
(12pts) 
-2.53 (+/- 1.27) -2.71 (+/- 0.96) -2.82 (+/- 0.57) -2.46 (+/- 0.46) 
 
 
 
Type of testosterone esters Number of patients 
Testosterone enanthate 91 
Testosterone undecanoate depot 36 
Testosterone undecanoate oral 4 
Testosterone cypionate 1 
Testosterone proprionate 1 
Primotestosterone 10 
Testogel 1 
Not specified in notes 9 
Type of testosterone esters Number of patients 
Testosterone enanthate 91 
Testosterone undecanoate depot 36 
Testosterone undecanoate oral 4 
Testosterone cypionate 1 
Testosterone proprionate 1 
Primotestosterone 10 
Testogel 1 
Not specified in notes 9 
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Patients were reviewed at 3-6 months (35%; 
n=54) and then annually (88%; n=135) after 
treatment was initiated.  Improvement of symptoms 
was documented in 50% (n=77) of the patients.  36 
patients stated that they felt better after the 
treatment was started, with improved erectile 
function in 32 patients.  13 patients had improved 
libido and 19 patients had increased body hair. 
80% (n=123) of the patients had annual 
haematocirt checked.  All of these patient 
haematocrit value was less than 54% and so 
testosterone treatment was not discontinued for this 
reason. 
33% (n=50) of the patients had BMD done 
prior to starting treatment with 16% (n=24) of these 
having follow- up BMD.  BMD were carried out on 
either Norland  and Hologic Bone Densitometers.  
BMD was assessed after starting treatment in 14% 
(n=22) of the patients.  20 patients were 
osteoporotic, 24 patients were osteopenic whilst 28 
patients had normal BMD. 
Table 2 displays patients who had BMD done 
at diagnosis and at follow up (16% of the patients).  
T score at the spine showed mild improvement in 
osteopenic and normal patients while slight 
deterioration was seen in osteoporotic patients.  T 
score at the hip showed some deterioration in 
normal and osteopenic patients while there was an 
improvement in osteoporotic patients.   
 
Discussion 
This analysis of concordance with guidelines 
highlights areas which need to be improved when 
managing patients with hypogonadism at Mater Dei 
Hospital. 
The gold standard methods to measure free 
testosterone values are liquid chromatography and 
mass spectrometry which are not available locally. 
Given this, total testosterone measurements are the 
best available option locally.7-8  Free testosterone 
estimation would be preferred in scenarios were 
total testosterone levels are near the normal range 
and in whom altered sex hormone binding globulin 
(SHBG) levels are suspected (e.g. obesity, diabetes, 
hypothyroidism).2,7  In our testosterone deficient 
patients, free and total testosterone serum levels 
were obtained at varying time points over the study 
period as a result of changes in the assays made 
available by the Pathology department at Mater Dei 
Hospital.   
ESCG state that a diagnosis of hypogonadism 
is established after two separate measurements of 
morning total testosterone levels are low.7  
However results of the study show that 24% of 
patients diagnosed with hypogonadism had only 1 
measurement.  A retrospective cohort study in USA 
also showed lack of duplicate confirmatory testing, 
with only 40% of the 63,534 cohort population 
having 2 or more testosterone levels 
determinations.9  However, all total testosterone 
serum testing was carried out in the morning, 
respecting testosterone’s diurnal variation and 
adhering to guidelines.7 This contrasts with a 
NorthShore University cohort study, were only 9% 
of men were tested in the early morning.2 Barriers 
to guideline implementation include lack of 
awareness and familiarity with guidelines, patient 
non- compliance or environmental barriers (such as 
difficulty scheduling early morning testing).2 
Karyotyping was not carried out in 65% of 
patients with primary hypogonadism. ESCG 
suggests that karyotyping is required to exclude 
Klinefelter syndrome (KS) in men with ‘’primary 
testicular failure of unknown aetiology’’.7   The 
incidence of KS is 0.1-2% of male neonates, being 
one of the commonest congenital disorders resulting 
in hypogonadism.10 Due to significant variation in 
clinical presentation, only 10% of cases are 
identified before puberty and 25% up until 
adulthood, with the latter reported in a study using 
Danish patient registries.10-11  Diagnosis should be 
made as early as possible in KS patients, as early 
treatment with testosterone helps improve their 
quality of life.11 Although a combination of small 
testes and elevated gonadotrophins is present in the 
majority of KS patients, variable phenotypes, as 
well as mosaicism, make karyotyping essential in 
all patients with primary hypogonadism of 
unidentified aetiology.10  
When diagnosing secondary hypogonadism; 
TSH, free thyroid hormone, prolactin, serum 
cortisol, IGF-1 and GH were assessed in the 
majority of patients (> 89%), whilst iron studies 
were documented in less than half of patients.  
ESCG suggest iron saturations be measured in all 
patients with secondary hypogonadism so as to 
exclude or confirm haemochromatosis.7 The largest 
study on prevalence of hypogonadism in 
haemochormatosis reported a prevalence of 
hypogonadism of only 6.4%.12  However, 
prevalence of hypogonadism may be decreasing due 
to earlier diagnosis of haemochromatosis.  
10
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Hypogonadism however still remains a significant 
complication and all patients with 
haemochromatosis should be screened for this.12  
Testosterone enanthate followed by 
intramuscular testosterone undecanoate were the 
two commonest prescribed testosterone replacement 
treatment, and are recommended by ESCG.7 
However, oral forms (which include testosterone 
undecanoate) are associated with a high serum level 
variability and require multiple daily doses 
compared to other routes of administration.13  This 
has significant implications with regards to 
compliance and efficacy.  Intramuscular injections, 
subcutaneous implants, patches and gel have 
demonstrable better pharmacokinetics, better long 
term outcome and should ideally be available for 
patients use.13-14  
With regards to patient follow-up, only 35% of 
patients were assessed at 3-6 months, whilst 88% 
were assessed annually, contrasting with the 
ESCG.7 Canadian and other international guidelines 
for the management of hypogonadism also 
recommend these monitoring intervals.1,4  This re-
assessment should incorporate details of 
improvement of symptoms, possible therapeutic 
complications, patient adherence and biochemical 
monitoring (including testosterone level and 
PSA).1,4 Shorter hospital outpatient appointment 
interval should therefore be recommended. 
A limitation in our study was that we only had 
access to hospital files and some of the patients may 
have been followed up in the community. ESCG 
recommends assessing whether symptoms have 
ameliorated with treatment and if there is 
documentation of any adverse effects.7 The BLAST 
study suggests that early sexual benefits and 
improvements  can be effectively documented 
through use of the Ageing Male Symptom score.5   
A prospective study by Kovac et al. also revealed 
that satisfied patients reported more significant 
improvements in the areas of libido, concentration, 
mood and muscle mass higher than dissatisfied 
patients.15 Adopting a standard method of symptom 
documentation on follow-up may help increase 
awareness for physicians, help identify patient 
complaints, and also indirectly increase treatment 
compliance and improve patient outcomes.  
When considering complications of 
hypogonadism, 33% of patients had a documented 
baseline BMD, with only 16% of these having 
follow-up BMD monitoring. 14% of the total study 
population had BMD assessments after starting 
testosterone treatment. However the number of 
patients was very small, the bone densitometry 
utilised was not the same in all patients and there 
may have been other confounding factors making it 
difficult to draw up any conclusion from these 
figures.  
In a randomized, double-blind, placebo-
controlled study, Basurto et al showed how BMD in 
the lumbar spine significantly improved with 
testosterone treatment.16  In a study done over 36 
months on patients with hypogonadism and 
metabolic syndrome, Aversa et al showed an 
improvement in BMD in both lumbar spine and hip 
with testosterone replacement.17  Treatment in 
hypogonadal men causes significant improvement 
in both hip and lumbar spine BMD, with significant 
effects on BMD reported after 6 months and an 8-
10% increase over 3 years.4-6,18  Due to the risk of 
decreased BMD and fractures in untreated 
hypogonadism, it is advisable to do bone 
densitometry at baseline (for future results 
comparison) and every 1-2 years of testosterone 
replacement.1,6,8  This enables surveillance regard 
treatment compliance, and improvement of BMD 
with treatment,  and subsequent appropriate dose 
adjustment  if BMD measurements are 
unsatisfactory.18  Other pathologies predisposing to 
osteopenia and osteoporosis should have been 
excluded prior to testosterone initiation.18  
With regards to PSA testing and monitoring in 
patients older than 40 years, 54% of hypogonadal 
patients had a documented PSA at baseline prior to 
treatment.  The association between testosterone 
replacement and prostate pathology is highly 
controversial.19  Study by McLaren et al. revealed 
that continuation of testosterone replacement over a 
2 year period did not raise PSA values, with 
minimal effect on prostate health.20  However, a 
meta-analysis of randomized, placebo-controlled 
trials of 19 studies by Calof et al, deduced that rates 
of prostate cancer, significant increments in PSA 
levels and increases in American Urological 
Association/International Prostate Symptom Score 
scores were higher in testosterone  treated men than 
the placebo group.14  However, significant bias was 
noted in that testosterone treated patients were more 
likely to undergo prostate screening and  biopsy 
than the placebo group.14  A critical review by 
Jannini et al, concluded that whilst prostate cancer 
is androgen- dependent, no conclusive evidence for 
11
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increased prostatic cancer/ hyperplasia is 
available.19  Therefore physicians should be cautious 
and monitor for prostate pathology.19  The general 
consensus for screening includes PSA and a digital 
rectal examination before and during patient follow-
up appointments.1,7,21  
 
 
Figure 8:  Algorithm in androgen deficiency patients 
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Figure 9: Algorithm regarding monitoring after starting testosterone treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Observations  
 Areas of good practice:  
- Early morning measurement of total 
 testosterone serum levels  
- When diagnosing causes of secondary 
 hypogonadism, a full pituitary hormonal profile 
 was requested 
- In a significant number of cases of secondary 
 hypogonadism, a form of imaging modality 
 was considered, generally CT or MRI 
- No patient who was prescribed testosterone 
 was known to have suffered from breast or 
 prostate cancer. 
 Areas for improvement:  
- Need for improved documentation of the signs 
 and symptoms of hypogonadism 
- Need for use of total testosterone testing as a 
 primary diagnostic test, with 2 separate tests 
 serving to confirm hypogonadism 
- Karyotyping should be considered in the 
 majority of testosterone deficient patients with 
 primary hypogonadism  
- Iron studies should be considered as part of the 
 diagnostic investigations 
- Need to take PSA prior to starting treatment in 
 those over 40 years 
- Need for shortened follow-up intervals 
 following treatment intervention  
- Need for improved documentation of patient 
 symptom alleviation and treatment side effects 
 on monitoring 
- Need to perform BMD in all patients prior to 
 starting treatment and follow up accordingly. 
- Option to analyse steroids by liquid 
 chromatography and mass spectrometry 
- Need to have male normative BMD values for 
 males 
 
Recommendations  
This analysis identified the need for 
documentation of the signs and symptoms and also 
to repeat testosterone levels prior to starting 
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treatment.  It also identified the need for 
karyotyping in patients with primary hypogonadism.  
The results also show the need to measure BMD 
and PSA before prescribing testosterone.  
Regarding follow up, this audit recognizes the need 
for earlier review at 3-6 months with proper 
documentation of symptoms. Repeat BMD should 
be done at 1-2 years after treatment initiation.  
Figure 8 and 9 are two algorithms which one can 
use when considering testosterone treatment in 
patients with androgen deficiency.   Finally, 
patients best served by review in a specialist clinic 
not in the community. 
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